Clinical Trials
41 trialsTucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
Peking Union Medical College Hospital
EXALT-2
Medical University of Vienna
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Legend Biotech USA Inc
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Ruijin Hospital
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
The First Affiliated Hospital with Nanjing Medical University
MUSCLE
UMC Utrecht
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma
Ruijin Hospital
Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Lanzhou Institute of Biological Products Co., Ltd
Allo-HSCT as First-line Consolidation in High-risk PTCL
Peking University People's Hospital
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Peking University People's Hospital
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
Hebei Senlang Biotechnology Inc., Ltd.
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
The First Affiliated Hospital of Bengbu Medical University
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Zhejiang University
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Fundamenta Therapeutics, Ltd.
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
The First Affiliated Hospital of Soochow University
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
iCell Gene Therapeutics
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
iCell Gene Therapeutics
CD5CAR-T
iCell Gene Therapeutics
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Shandong Provincial Hospital
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
The University of Hong Kong
CHEMO-T
Royal Marsden NHS Foundation Trust
Tcell-Brazil
Grupo de Estudos Multicentricos em Onco-Hematologia
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Shandong Provincial Hospital
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
Peking Union Medical College Hospital
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
Far Eastern Memorial Hospital
A-CHOP-14
University of Göttingen
Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
Chonnam National University Hospital
FAD
Fudan University
PTCL
Fudan University